Adjuvant endocrine treatment has shown to improve survival in breast cancer patients with hormone-receptor (HR)-positive disease, with tamoxifen being the treatment of choice for premenopausal women whereas AIs are preferred options in postmenopausal women [1, 2]. This evidence concerns the gene NR4A1 and breast cancer.